Welcome to our dedicated page for Legend Biotech SEC filings (Ticker: LEGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Legend Biotech Corporation (NASDAQ: LEGN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer. Legend Biotech files annual reports on Form 20‑F and frequent current reports on Form 6‑K, which together outline its financial performance, cell therapy pipeline, and key business developments.
In these filings, Legend Biotech presents unaudited interim condensed consolidated financial statements, including statements of profit or loss, financial position, changes in equity, and cash flows. Investors can review details on license revenue, collaboration revenue related to CARVYKTI® (ciltacabtagene autoleucel; cilta‑cel), research and development expenses, selling and distribution expenses, and collaboration funding arrangements. Management’s Discussion and Analysis (MD&A), often attached as exhibits to Form 6‑K, provides narrative context around revenue drivers, cost trends, and liquidity.
Filings also capture clinical and regulatory milestones. Recent 6‑Ks incorporate press releases on CARTITUDE‑1, CARTITUDE‑4, and CARTITUDE‑6 study updates, FDA and European Commission label changes for CARVYKTI, and early data from programs such as LUCAR‑G39D, LB2102, and LB1908. Additional 6‑Ks describe agreements with Janssen for component and product supply, preliminary sales figures for CARVYKTI, and participation in major scientific and investor conferences.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy 6‑K and 20‑F filings, helping users quickly identify information on revenue composition, cell therapy pipeline status, collaboration structures, and risk disclosures. Real‑time ingestion of EDGAR updates ensures that new Legend Biotech filings, including any Form 6‑K related to financial results or material agreements, appear promptly.
Users can also monitor equity and compensation-related disclosures via Legend Biotech’s registration statements on Form S‑8, as referenced in its 6‑K reports, and review how these interact with share‑based compensation expenses reported in the financial statements. While Legend Biotech does not file Forms 3, 4, and 5 as a U.S. domestic issuer would, this page centralizes its available SEC reporting so investors can follow the company’s development as a global cell therapy business.
Legend Biotech Corp Chief Executive Officer Ying Huang reported the sale of 9,936 ordinary shares on March 25, 2026. The weighted average price was $8.77 per ordinary share. According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted share units. Following this transaction, Huang directly holds 247,438 ordinary shares.
LEGN filed a Form 144 reporting the proposed sale of 4,968 American Depositary Shares following restricted stock vesting on 03/20/2026. The filing lists trading on NASDAQ and records a prior sale by Ying Huang of 64,339 American Depositary Shares on 12/26/2025 for $1449074.23.
Legend Biotech Corp director Tomas J. Heyman has filed an initial ownership report outlining his equity position in the company. He directly holds 32,734 ordinary shares, which include 25,674 restricted share units that vest in staged quarterly installments beginning on March 20, 2026 and a larger tranche starting on June 20, 2026, subject to continued service. He also holds a share option over 30,000 ordinary shares at an exercise price of $23.27 per share, expiring on August 1, 2032. Of these option shares, 18,000 are immediately exercisable, with the remaining 12,000 vesting in two equal annual installments beginning on August 2, 2026. Each American Depositary Share represents two ordinary shares.
Legend Biotech Corp filed an initial insider ownership report for director Robin Meng on Form 3. This filing establishes Meng’s status as a reporting insider but shows no reported transactions or holdings, indicating that only insider status, not trading activity, is being disclosed at this time.
Legend Biotech Corp director Peter Salovey filed an initial ownership report showing 26,766 restricted share units (RSUs) tied to the company’s ordinary shares. Each RSU represents a right to receive one ordinary share upon settlement, and the shares may also be represented by ADSs, with each ADS equal to two ordinary shares.
The filing notes that 5,216 RSUs have already settled. Of the remaining awards, 7,306 RSUs are scheduled to vest in six equal quarterly installments beginning on March 20, 2026. Another 14,244 RSUs are scheduled to vest with 25% on June 20, 2026 and the balance in eight equal quarterly installments, subject to Salovey’s continued service to the company.
Legend Biotech Corp director Casey Patrick John filed an initial ownership report showing existing equity holdings. The filing lists 54,604 Ordinary Shares held directly, including 25,674 restricted share units that vest in scheduled quarterly installments starting on March 20, 2026 and June 20, 2026. It also reports a Share Option for 30,000 Ordinary Shares at an exercise price of 14.1200 per share, expiring on March 28, 2031, which is immediately exercisable. The company notes each ADS represents two Ordinary Shares.
Legend Biotech Corp director Gareth Kung filed an initial ownership report showing 31,486 restricted share units (RSUs). Each RSU represents a contingent right to receive one ordinary share. Twenty-five percent of the RSUs vest on February 2, 2027, with the remainder vesting in eight equal quarterly installments beginning March 20, 2027, subject to continued service. The company’s ordinary shares may also be represented by American Depositary Shares, with each ADS equal to two ordinary shares.
Legend Biotech Corp director Mao Li filed an initial ownership report showing existing equity awards rather than new trades. The filing lists a share option covering 30,000 ordinary shares at an exercise price of 23.2700 per share, expiring on August 1, 2032. Footnotes state 18,000 of these option shares are already exercisable, with the remainder vesting in two equal annual installments starting on August 2, 2026, subject to continued service.
The report also shows direct ownership of 44,330 ordinary shares, including 25,674 restricted share units that convert into one ordinary share each upon settlement. These RSUs vest in multiple quarterly installments beginning on March 20, 2026, and in a larger grant with an initial vest on June 20, 2026 followed by additional quarterly vesting dates. The company notes its ordinary shares may be represented by American Depositary Shares, with each ADS equal to two ordinary shares.
Legend Biotech Corp director Ji Darren Xiaohui reported his initial ownership on a Form 3. He directly holds 63,773 ordinary shares, including 34,662 restricted share units that vest in staged quarterly installments through future dates. He also holds an option immediately exercisable for 30,000 ordinary shares at an exercise price of 11.50, expiring on June 5, 2030. Each American Depositary Share represents two ordinary shares.